Skip to content

IEMbase 0158: TK2-related mitochondrial DNA depletion syndrome 2

Scope

Field Value
IEMbase ID 158
Nosology 9.1.06.01
Gene TK2
External IDs OMIM:609560; OMIM:188250; ORPHA:254875
Generated mapping CANDIDATE to Mitochondrial_Neurogastrointestinal_Encephalomyopathy.yaml
Candidate DisMech targets Mitochondrial_Neurogastrointestinal_Encephalomyopathy.yaml
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents this as TK2-related mitochondrial thymidine kinase 2 deficiency, with alternate labels mitochondrial DNA depletion syndrome type 2 and MTDPS2. Treatability is marked unknown, but the JSON contains a pharmacological deoxynucleoside treatment row.

The biochemical profile includes increased plasma creatine kinase, increased plasma lactate, decreased muscle cytochrome c oxidase activity, and increased histochemical mitochondrial proliferation in muscle. Clinical rows include muscle mitochondrial DNA depletion, hypotonia, myopathy, ophthalmoplegia or ophthalmoparesis, peripheral neuropathy, neurological symptoms, spinal muscular atrophy-like presentation, and perinatal death.

DisMech phenotype coverage

The generated MNGIE candidate is not a valid mapping. The local MNGIE entry is anchored on TYMP deficiency, thymidine/deoxyuridine accumulation, and neurogastrointestinal disease, with POLG and RRM2B listed only as distinct MNGIE-like phenotypes. It does not model TK2 mitochondrial thymidine kinase 2 deficiency or MTDPS2.

Local references to TK2 occur in Autosomal_Dominant_Cerebellar_Ataxia_Type_III.yaml as part of a BEAN1/TK2-region SCA31 repeat locus. That is an intronic repeat-associated cerebellar ataxia context, not biallelic TK2 enzyme deficiency with mitochondrial DNA depletion.

Concordance and completeness

Judgement: false-positive candidate; true local gap.

The MNGIE candidate shares broad mitochondrial nucleotide-pool and ophthalmoplegia language, but the disease identity is wrong. IEMbase 158 is a TK2 myopathic mitochondrial DNA depletion syndrome with CK/lactate, COX deficiency, mitochondrial proliferation, mtDNA depletion, severe hypotonia and myopathy, and early lethality. That phenotype is not represented by the current MNGIE or SCA31 entries.

Curation actions

  • Leave IEMbase 158 unmapped for now.
  • Future curation should create a TK2/MTDPS2 entry if this disease is in scope.
  • Preserve deoxynucleoside therapy, muscle mtDNA depletion, CK/lactate, COX, and ophthalmoparesis as key leads for that future entry.